The new registration module facilitates expanded access to novel therapies for patients with advanced cancer while accelerating the generation of real-world data on safety and efficacy.
SAN FRANCISCO, CA, NOVEMBER 17. Today, xCures Inc. is launching xACCESS – a new registration module for their AI-assisted clinical study platform. The module is used to enroll cancer patients and empower them, and their physicians, to make informed decisions and learn about access to treatment programs. The xCures platform uses a Master Observational Registry to efficiently run a wide variety of oncology studies and decentralized trials, prospectively generating real-world evidence.
“xACCESS is xCures’ first patient-centric technology module, onboarding patients directly to our sponsored studies and partner programs,” stated Mika Newton, xCures’ CEO. “This is an important milestone on our journey to make the cancer treatment ecosystem work better for patients and facilitating access to the best treatment options.”
The xACCESS registration module enables rapid scaling by eliminating bottlenecks in eConsenting and acquiring medical records, providing benefits to patients, physicians, partners, payers, sponsors, and investors. The resulting Real-World Evidence (RWE) supports the assessment of safety, efficacy, and utility of investigational and approved cancer therapies.
The xACCESS module will be used for all clinical studies and programs available on the xCures platform, including the recently announced Compassionate Use program for ulixertinib (BVD-523), currently enrolling patients with MAPK pathway aberrant cancer.
xCures Inc. operates an AI-assisted clinical platform that connects cancer patients/physicians with optimal investigational or approved therapies. The platform prospectively generates real-world evidence for clinical studies and decentralized trials. For more information, visit www.xcures.com and or contact firstname.lastname@example.org